Physician profile
Christopher Schmitt
NPI 1548210370
$4,184.11
in general payments reported to CMS, 2019-2025
25 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $966 · 2021: $46.21 · 2022: $276 · 2023: $710 · 2024: $273 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.13 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,115.75 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Hill-Rom Services, INC | $840.00 | 2019 | |
| Hill-Rom Holdings, INC | $800.00 | 2020 | |
| Genzyme Corporation | $273.31 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $174.63 | 2019-2023 | Breztri, Symbicort, Tezspire |
| Sunovion Pharmaceuticals INC. | $173.21 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.51 | 2019-2023 | Ofev |
| Genentech USA, INC. | $95.46 | 2019-2023 | Xolair, Esbriet |
| Amgen INC. | $83.74 | 2022-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $66.83 | 2023 | Dupixent |
| Pulmonx Corporation | $64.94 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Sanofi-Aventis U.S. LLC | $57.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.77 | 2022-2024 | Glassia |
| Philips North America LLC | $32.49 | 2022-2023 | |
| Astellas Pharma US INC | $25.03 | 2019-2023 | Cresemba |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $24.72 | 2021-2024 | Tyvaso |
| Medtronic, INC. | $23.27 | 2025 | Bis |
| Mylan Specialty L.P. | $23.26 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.57 | 2019 | |
| Veran Medical Technologies, INC. | $18.41 | 2019 | |
| Inogen, INC. | $18.25 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Grifols USA, LLC | $16.69 | 2024 | Prolastin-C Liquid |
| Advanced Respiratory, INC | $16.26 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.46 | 2020 | |
| Mayne Pharma Commercial LLC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Schmitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.